Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27043895 | 0.84 | RIPK1 (0.44) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL8137111 | 0.78 | RIPK1 (0.41) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24476085 | 0.76 | RIPK1 (0.40) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15434422 | 0.76 | USP2 (0.38) | USP2ALOX15 | |
| SCHEMBL12392730 | 0.74 | KDM4E (0.46) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9814035 | 0.74 | TSHR (0.47) | USP2ALOX15 | |
| SCHEMBL28551868 | 0.73 | BRD4 (0.37) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9010937 | 0.73 | RIPK1 (0.37) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1712608 | 0.73 | MAPT (0.46) | RIPK1ALOX15MEN1CYP3A4CYP2C9 | |
| SCHEMBL1712606 | 0.73 | RIPK1 (0.37) | RIPK1MEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |